Sanofi-Aventis Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on September 14, 2004, by Sanofi-Aventis (formerly Sanofi-Synthelabo), discloses the publication of its consolidated financial statements and management report for the six months ended June 30, 2004. The documents were published in the French official gazette (BALO) on September 8, 2004, and are incorporated by reference into the company's Registration Statement on Form F-4.
Key Financial Metrics
The filing text serves as a cover document and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached exhibits (Exhibit 99.1: Consolidated Financial Statements and Exhibit 99.3: Management Report), which are referenced but not reproduced in the provided text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached Management Report and Financial Statements for comparative analysis.
Guidance, Outlook, and Risks
The Management Report (Exhibit 99.3) includes forward-looking statements regarding sales and earnings prospects. Management cautions that actual results may differ materially due to various risks, including:
- The ability to expand profitably in the United States.
- The success of research and development programs.
- The ability to protect intellectual property rights.
- Risks associated with healthcare cost reimbursement and pricing reforms, particularly in the U.S. and Europe.
Sanofi-Aventis does not undertake any obligation to update or revise these forward-looking statements.
Investor Verification Checklist
- Review Exhibit 99.1 for specific revenue, net income, and cash flow figures for the six months ended June 30, 2004.
- Examine Exhibit 99.3 for detailed management commentary on sales growth and earnings guidance.
- Verify the impact of U.S. market expansion and R&D pipeline progress on future projections.
- Assess the potential impact of healthcare pricing reforms in the U.S. and Europe on future margins.